Kuo Minnie 4

What Happened

• Minnie Kuo, Chief Operating Officer of Pliant Therapeutics (PLRX), was granted a derivative award covering 300,000 shares on January 22, 2026. The Form 4 reports the acquisition amount as $0 (transaction code A — grant/award).

Key Details

• Transaction date: 2026-01-22; filing date: 2026-01-26 (filed on time).
• Reported amount: 300,000 shares as a derivative instrument; reported price $0.00 on the Form 4.
• Vesting: 1/48th of the shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to continuous service (see footnote).
• Shares owned following the transaction: not specified in the provided filing details.
• Transaction code: A (award/grant); footnote describes monthly vesting; no 10b5‑1, tax‑withholding, or sale details reported.

Context

• This was an option/award grant with a multi-year monthly vesting schedule — not an immediate market purchase or sale. Such grants align compensation with continued service and future company performance; they do not necessarily indicate immediate buying or selling by the insider. The filing appears timely (filed within the required reporting window).